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Simple Summary: Despite recent advances, some patients with pancreatic cancer are refractory to
treatment and the disease rapidly progresses, resulting in early death. The potential prognostic value
of circulating tumor cells (CTCs) has been demonstrated in other cancer types, but the clinical validity
in pancreatic cancer remains elusive. Here, we show that CTC clusters, which show mesenchymal
characteristics and platelet marker expression, are highly correlated with poor prognosis in patients
with unresectable pancreatic cancer.
Abstract: Circulating tumor cells (CTCs) are known to be heterogeneous and clustered with tumor-
associated cells, such as macrophages, neutrophils, fibroblasts, and platelets. However, their molecu-
lar profile and clinical significance remain largely unknown. Thus, we aimed to perform a comprehen-
sive gene expression analysis of single CTCs and CTC clusters in patients with pancreatic cancer and
to identify their potential clinical relevance to provide personalized medicine. Epitope-independent,
rapid (>3 mL of whole blood/min) isolation of single CTCs and CTC clusters was achieved from a
prospective cohort of 16 patients with unresectable pancreatic cancer using a centrifugal microfluidic
device. Forty-eight mRNA expressions of individual CTCs and CTC clusters were analyzed to
identify pancreatic CTC phenotype. CTC clusters had a larger proportion of mesenchymal expression
than single CTCs (p = 0.0004). The presence of CTC clusters positively correlated with poor prognosis
(progression-free survival, p = 0.0159; overall survival, p = 0.0186). Furthermore, we found that most
CTCs in these patients (90.7%) were cloaked with platelets and found the presence of a positive
correlation between the increase in CTC clusters and rapid disease progression during follow-ups.
Efficient CTC cluster isolation and analysis techniques will enhance the understanding of complex
tumor metastasis processes and can facilitate personalized disease management.
Keywords: circulating tumor cells; circulating tumor cell clusters; pancreatic cancer; platelets
1. Introduction
Pancreatic cancer is a leading cause of cancer mortality worldwide [1,2]. Pancreatic
cancer showed a dismal prognosis with a 5-year survival rate of <9% because most pa-
tients were diagnosed in the late phase owing to rapid progression and early metastasis
associated with the disease [3]. Although recent advances in therapeutic options such as
the FOLFIRINOX regimen and gemcitabine with nab-paclitaxel showed survival benefits
in patients with advanced pancreatic ductal adenocarcinoma (PDAC), some patients may
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be refractory to these chemotherapeutic agents, resulting in rapid disease progression and
early death. Therefore, better predictive biomarkers are needed to select proper candidates
for chemotherapy with unresectable pancreatic cancer [3].
Circulating tumor cells (CTCs) are good candidates for prognostic biomarkers since
their evaluation is minimally invasive and therefore allows for more frequent monitoring
of the real-time dynamics of cancer progression [2–6]. Despite the potential benefits [7–10],
the clinical utility of CTCs in pancreatic cancer has not been fully elucidated, partly
because of the intrinsic difficulties associated with the rareness and heterogeneity of CTCs.
While many previous studies have used immunoaffinity-based CTC capture using anti-
epithelial cell adhesion molecule (EpCAM) antibodies, emerging evidence suggests that
CTCs undergo epithelial–mesenchymal transition (EMT) to enter the bloodstream and
seeding distant organs. Therefore, it is essential to enrich CTCs independent of the surface
markers and to characterize CTCs at a single-cell level to understand the phenotype
heterogeneity and dynamics as well as their potential clinical relevance [2,6].
CTCs can migrate through the stroma and blood vessels not only as single cells but
also as clusters, which are groups of two or more aggregated CTCs [10–13]. Several studies
have suggested that CTC clusters might be related to a higher metastatic potential or poor
prognosis. In the early 1970s, a greater association of CTC clusters with distal metastasis
than of single CTCs was demonstrated through a series of preclinical studies [14,15]. The
prognostic value of CTC clusters has been demonstrated in recent studies on patients
with lung, breast, and prostate cancers [11,16–18]. In PDAC, CTC clusters (also circulating
tumor microemboli) were shown to be an independent prognostic factor of progression-free
survival (PFS) and overall survival (OS) [10].
Not only the enumeration of CTC clusters but also their molecular characterization is
important for discovering their potential clinical implications. Molecular analysis of CTC
clusters can provide additional insights into the mechanisms, including how CTC clusters
can survive during circulation and generate distant metastases. A promising hypothesis is
related to the non-tumorous components of CTC clusters, such as platelets, neutrophils,
macrophages, and fibroblasts, which are expected to offer a survival advantage by shield-
ing CTC clusters from shear forces, environmental or oxidative stresses, and immune
assault [19–24]. However, to date, only a few studies have reported the molecular character-
ization of patient-derived PDAC CTC clusters and their clinical implications [25–27]. An
in-depth understanding of the molecular characteristics of CTC clusters and their clinical
significance is required to provide more effective precision medicine options.
Thus, we aimed to achieve a comprehensive phenotypic characterization of CTC
clusters based on mRNA profiling and to demonstrate a correlation between the molecular
phenotype of CTC clusters and clinical outcomes in patients with unresectable pancreatic
cancer. We performed phenotypic characterization of CTCs based on mRNA profiling of
individual CTCs or CTC clusters using a multiplex polymerase chain reaction chip capable
of simultaneous analysis of 48 genes that are associated with EMT phenotypes, stemness,
and the presence of platelets, neutrophils, macrophages, and fibroblasts.
2. Results
2.1. Patients’ Characteristics and CTC Enumeration
We employed a centrifugal microfluidic device, the FAST disc, to achieve label-free
isolation of CTCs from whole blood samples without pretreatment [28,29]. Single CTCs
showing CD45− and DAPI+ expression and CTC clusters captured on the membrane of
the FAST disc were picked without fixation and used for molecular analysis (Figure 1A).
To investigate the heterogeneity of CTCs and their interaction with other cell types in the
blood microenvironment, we analyzed genes associated with EMT, proliferation, and other
types of cells, including platelets, macrophages, neutrophils, and fibroblasts (Table S1). In
addition, we performed immunofluorescence staining (Figures 1B and S1) and took SEM
(Figures 1C and S2) images to visualize CTCs and CTC clusters and to test conventional
criteria for CTC identification, DAPI+, EpCAM/CK+, and CD45−.
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Figure 1. Scheme of circulating tumor cell (CTC) characterization. (A) Scheme of CTC characteriza-
tion using mRNA profiling. (B) Immunofluorescence image of CTCs and white blood cell (WBC)
(scale bar: 50 µm). (C) Scanning electron microscope images of single CTC and CTC cluster.
Overall, 16 patients (mean age, 66.9 years; range, 51–80 years) with histologically
proven PDAC between March 2018 and October 2019 were enrolled (Table S2). For all
patients, the initial blood draw was collected in treatment-naïve status (baseline, V0). Six
patients were followed up at an interval of 2–3 months with a blood draw. Eleven of the
16 patients (68.8%) were diagnosed with metastatic disease and the other five patients with
locally advanced disease. The median follow-up time for all patients was 228 days (range,
45–381 days). Fourteen patients (87.5%) showed disease progression during a median
follow-up of 129 days (range, 45–303 days). One patient died owing to sudden cardiac
arrest. Three patients (S007, S018, and S025) died without any image follow-up within
60 days. These patients were defined as the rapid progression in metastasis (RP-M) group,
and the other 13 patients (81.3%) who survived for more than 60 days were defined as the
non-rapid progression in metastasis (non-RP-M) group. From the RP-M group, 9 single
CTCs and 34 CTC clusters were detected; CTC clusters constituted 79.1% among the total
of 43 CTCs, while 23 single CTCs and 11 cl sters were detected in the non-RP-M
group.
At baseline, the detection rate of CTC clusters was much higher in pancreatic cancer
patients with m tastatic disease (5/11, 45.5%) than tho e wit locally advanc d disease
(1/5, 20.0%). A ong he five p ti nts with metastatic pancreat c cancer with CTC clust rs,
three patients were classified into the RP-M group. The other six patients among the
11 patients with metastatic disease and without CTCs were classified into the non-RP-M
group.
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2.2. Molecular Characterization of Heterogeneity of Five Pancreatic Cancer Cell Lines
Before the analysis of patient-derived CTCs, we first tested five pancreatic cancer
cell lines: BxPC-3, PANC-1, Capan-1, HPAC, and MIA PaCa-2. After FAST disc opera-
tion similar to the patients’ sample processing using blood samples spiked with cancer
cells (~500 cells/3 mL), each live cell captured on the membrane (n = 5 per cell type)
was collected using a single-cell manipulation technique and was subjected to mRNA
expression analysis. The t-SNE analysis was able to recapitulate five different cell clusters
corresponding to different cell lines (Figure S4A). In the correlation matrix plot show-
ing Spearman’s correlation coefficient among 25 individual cells from the five different
cell lines (Figure S4B), the mesenchymal cell lines (HPAC and MIA PaCa-2) showed a
highly positive correlation with each other but showed a strong negative correlation with
the other epithelial cell lines (BxPC-3, PANC-1, and Capan-1). Additionally, our mRNA
expression-based single-cell scoring system [29] could clearly recapitulate well-known
characteristics of each cell line (Figure S4C–F). The epithelial cell lines achieved significantly
higher scores for epithelial markers, namely KRT 19, KRT7, and CDH1, with scores of
91.5 ± 7.0, 72.9 ± 21.4, and 78.8 ± 2.9 for BxPC-3, PANC-1, and Capan-1, respectively,
and 13.9 ± 25.7 and 6.5 ± 1.2 for HPAC and MIA PaCa-2, respectively. In contrast, the
mesenchymal scores related with mesenchymal markers (vimentin, SPARC, and SNAI1)
were 0.5 ± 0.7, 8.5 ± 15.1, and 0.0 ± 0.0 for BxPC-3, PANC-1, and Capan-1, respectively,
and 49.3 ± 41.4 and 50.8 ± 11.8 for HPAC and MIA PaCa-2, respectively. Moreover, the
expression of stem-cell-like markers (CD44, NANOG, and PROM1) was slightly higher in
the mesenchymal cell lines, with scores of 8.0 ± 6.4, 18.6 ± 9.0, and 21.2 ± 2.9 for BxPC-3,
PANC-1, and Capan-1, respectively, and 36.8 ± 33.6 and 42.7 ± 12.6 for HPAC and MIA
PaCa-2, respectively.
2.3. mRNA Expression Profiling of Patient-Derived Single CTCs and CTC Clusters
mRNA profiling was performed on 77 CTCs (single CTCs (n = 32) and CTC clus-
ters (n = 45)) from eight patients to analyze their molecular characteristics. Among them,
62 CTCs were obtained from the blood samples at baseline before chemotherapy, and
the other 15 CTCs were obtained after chemotherapy. Unsupervised hierarchical cluster-
ing showed that the gene expression patterns were distinctive depending on the origin
(Figure 2A). Despite the heterogeneity of individual CTCs and CTC clusters, CTCs from
the same patient were clustered together as presented in the t-SNE plot (Figure 2B) and the
correlation matrix (Figure 2C).
Furthermore, very distinctive differences in mRNA expression patterns between
32 single CTCs and 45 CTC clusters were observed (Figure 3A). The epithelial score was
higher for single CTCs (46.5 ± 34.6 and 23.0 ± 33.4 for single CTCs and CTC clusters,
respectively; p = 0.004), while the mesenchymal score was distinctively higher for CTC
clusters (29.1 ± 39.7 and 63.6 ± 39.4 for single CTCs and CTC clusters, respectively;
p = 0.0004). The stemness marker score was slightly higher for single CTCs than for CTC
clusters (24.4 ± 23.6 and 13.4 ± 22.7 for single CTCs and CTC clusters, respectively;
p = 0.046) (Table S3 and Figure 3B).
2.4. Platelet-Associated Genes in Single CTCs and CTC Clusters
Consistent with previous studies reporting pro-tumorigenic roles of platelets in tumor
metastasis [30–39], we could identify platelet-covered CTCs in the fluorescence and SEM
images (Figures 3C, S2C and S3). Platelet markers were present in both single CTCs and
CTC clusters but were higher in CTC clusters (43.75% vs. 80%) (Figure 3A,D).
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Figure 2. Clustering of patient-derived CTCs according to the sample source. (A) Heat map for hierarchical cluster-
ing of the differentially expressed gene expression profiles of a single cell, color-coded, from eight different patients.
(B) Two-dimensional t-SNE analysis based on hierarchical clustering of eight pancreatic cancer patients in two groups
according to the progression (rapid progression in metastasis (RP-M): progression in metastasis for <60 days; non-rapid pro-
gression in metastasis (non-RP-M): progression in metastasis for >60 days). (C) Correlation matrix plot for eight pancreatic
cancer patients. t-SNE, t-distributed stochastic neighbor embedding.
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between the PLT+ group and the PLT− group. Box plots show 25th and 75th percentiles, with lines indicating the median 
Figure 3. Circulating tumor cell (CTC) characterization according to the subtypes. (A) CTCs classified into three categories
(epithelial, stem-like, and mesenchymal CTCs) according to their subtypes: (1) CTC-S (single CTC) or CTC-C (CTC cluster)
and (2) PLT+ group (platelet marker-positive group) or PLT− group (platelet marker-negative group). (B) The score of the
three categories between CTC-S and CTC-C. Box plots show 25th and 75th percentiles, with lines indicating the median
value and black square dots indicating the mean value. All the differences for the thre categories betwee the two g oups
are statistically ignificant (* p < 0.05, ** p < 0.01, *** p < 0.001). (C) Fluorescence images of CTC-S (left) and CTC-C (right)
with P-selectin-stained platelets at 60× (scale bar: 10 µ ). (D) Fisher’s exact test based on the analysis of contingency tables
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between CTC-S and CTC-C according to the platelet marker expression (p = 0.0015). (E) The score for the three categories
between the PLT+ group and the PLT− group. Box plots show 25th and 75th percentiles, with lines indicating the
median value and black square dots indicating the mean value. The differences between the two groups for epithelial and
mesenchymal scores are statistically significant (*** p < 0.001; NS: non-significant).
Next, we characterized the molecular makeup of individual CTCs depending upon
the presence of platelet markers. CTCs were divided into two groups according to the
presence of platelet marker expression: PLT+ group (at least one among three platelet
markers (ITGA2b, SELP, and PDGFb)) and PLT− group (no platelet marker expression).
Among the CTCs in the PLT+ group, 72.0% were CTC clusters and 28.0% were single CTCs
(Figure 3A). The PLT+ group showed significantly lower epithelial scores (20.7 ± 28.7 vs.
55.1 ± 37.0; p = 0.00003) and significantly higher mesenchymal scores (64.4 ± 38.2 vs.
21.2 ± 36.9; p = 0.00001) than the PLT− group. Among the four different categories of
CTCs, depending upon the presence of platelet markers and cluster form, the PLT+/CTC
cluster group showed the highest mesenchymal scores (73.0%), while the epithelial scores
were highest in the PLT−/single CTC group (55.8%) (Figure 3E and Table S4).
2.5. Genes Associated with the Alliance of CTCs to Evade the Immune System
Approximately 80% of CTC clusters were associated with platelets, and we also
investigated other types of blood cells in CTC clusters. Two immune cells (macrophages
and neutrophils) and one stromal cell type (fibroblasts), which are known to be associated
with the tumor microenvironment, were analyzed as well. CTC clusters showing positive
expression of at least one macrophage-related marker (CD68, CD14, or ADGRE1) were
defined as Mac+ CTC clusters. Similarly, CTC clusters with at least one neutrophil-related
marker (CD45, CSF3R, or ITGAM) were defined as Neu+ CTC clusters. CTC clusters with
fibroblast-related markers were defined as Fib+ CTC clusters.
Overall, 39 of the 45 CTC clusters (86.7%) expressed at least one stromal or immune
cell marker. Among the 39 CTC clusters with stromal or immune cells, 32 CTC clusters
(82.1%) expressed platelet markers (Figure S5 and Table S5). Approximately 92.6% of Mac+
CTC clusters, 88.5% of Neu+ CTC clusters, and 75.0% of Fib+ CTC clusters had platelet
marker expression, which may imply the role of platelets in the adherence of cells to form
CTC clusters (Table S5).
2.6. CTC Clusters Are Cloaked with Platelets and Correlate with Poor Prognosis in Patients with
Pancreatic Cancer
We further analyzed the CTC characteristics based on the clinical outcomes. Among
the eight patients whose CTCs were detected, clinical assessments were divided into RP-M
and non-RP-M groups. As shown in the X-ray and CT images in Figure S6, three patients
(S007, S018, and S025) in the RP-M group showed rapid progression of metastasis or an
increased tumor mass. Of the 77 CTCs detected in eight patients, 43 CTCs (56%) were
from those three patients in the RP-M group. Notably, 76% of CTC clusters (34/45) were
detected in those three patients in the RP-M group (Figure 4). Single CTCs and CTC
clusters accounted for 20.9% (9/43) and 79.1% (34/43), respectively, in the RP-M group. It
is important to note that not only CTC clusters (82.6%) but also single CTCs (65.4%) in the
RP-M group showed high mesenchymal scores (Table S6). Figure 4A clearly demonstrates
that CTCs in the RP-M group showed significantly higher mesenchymal characteristics
than those in the non-RP-M group (79.0 ± 26.4 vs. 11.7 ± 27.9; p < 0.001, Figure 4B). Despite
the heterogeneity of individual CTCs, the t-SNE analysis clearly identified CTCs based on
the clinical outcomes (RP-M group vs. non-RP-M group) (Figure 4C). We further analyzed
the association of platelet marker expression and clinical outcome. Most CTCs in the RP-M
group (90.7%) had platelet marker expression, while more than half of the CTCs in the
non-RP-M group (67.7%) had no platelet marker expression (Figure 4D).
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The presence of single CTCs did not correlate with survival (PFS, p = 0.9846; OS, p = 
0.7330) (Figure 5A,B). However, the presence of CTC clusters was strongly related to PFS 
and OS (PFS, p = 0.0159; OS, p = 0.0186) (Figure 5C,D). 
Figure 4. Circulating tumor cell (CTC) characterization according to the progression. (A) CTC classification into three
categories between the rapid progression in metastasis (RP-M) group and the non-rapid progression in metastasis (non-RP-
M) group according to subtypes: (1) CTC-S (single CTC) or CTC-C (CTC cluster) and (2) PLT+ group (platelet marker-positive
group) or PLT− group (platelet marker-negative group). (B) The score of the three categories between the RP-M group and
non-RP-M group (** p < 0.01, *** p < 0.001). (C) wo-dimensional t-SNE analysis based on hierarchical clustering between
the RP-M group and non-RP-M group. (D) Fisher’s exact test based on the a alysis of contingency tables between th RP-M
and non-RP-M groups according to the platelet marker expression (p < 0.0001). t-SNE, t-distributed stochastic neighbor
embedding.
The presence of single CTCs did not correlate with survival (PFS, p = 0.9846; OS,
p = 0.7330) (Figure 5A,B). However, the presence of CTC clusters was strongly related to
PFS and OS (PFS, p = 0.0159; OS, p = 0.0186) (Figure 5C,D).
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ing follow-ups. Furthermore, two more patients (S016 and S010) were available to observe 
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did not present any evidence of progression based on the CT finding and CA 19-9 level. 
However, the patient showed new liver metastasis with more increased CTCs. We ob-
served an increased number of CTC clusters 71 days before the evidence of progression 
using CT (Figure 6A). The other patient (S010) with a metastatic liver mass showed CTC 
clusters at baseline. Although the size of the liver mass increased by <20%, the CA 19-9 
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Figure 5. Survival analysis. (A) Progression-free survival and (B) overall survival according to the presence of CTC-S (single
CTCs) among the 16 pancreatic cancer patients. (C) Progression-free survival and (D) overall survival according to the
presence of CTC-C (CTC clusters) among the 16 pancreatic cancer patients. CTC-S (+) and CTC-C (+) are for the patients
who have one or more single CTCs and CTC clusters, respectively. CTC-S (-) and CTC-C (-) are for the patients who do not
have single CTCs and CTC clusters, respectively.
There were six patients who underwent chemotherapy and had more than one blood
draw during follow-ups. In two patients with locally advanced disease (S013 and S019), no
CTCs were detected at baseline and during follow-up and no progression was observed.
Two patients with locally advanced disease (S012 and S020) showed relatively long PFS
based on several single CTCs at baseline and a decreased number of CTCs during follow-
ups. Furthermore, two more patients (S016 and S010) were available to observe the changes
in CTC cluster counts and the changes in carbohydrate antigen 19-9 (CA 19-9) level because
of their sequential blood sampling (>3 time points, including baseline). One patient with
locally advanced disease (S016) showed an increased number of CTCs during the first
follow-up even though she did not have CTCs at baseline; moreover, she did not present any
evidence of progression based on the CT finding and CA 19-9 level. However, the patient
showed new liver metastasis with more increased CTCs. We observed an increased number
of CTC clusters 71 days before the evidence of progression using CT (Figure 6A). The other
patient (S010) with a metastatic liver mass showed CTC clusters at baseline. Although
the size of the liver mass increased by <20%, the CA 19-9 level decreased after starting
chemotherapy. Finally, the liver mass showed progression according to the Response
Evaluation Criteria in Solid Tumors at six months after starting chemotherapy. The patient
did not show C C clusters after starting chemotherapy; however, when she ad a sudden
increase i t e liver mass, her CTC cluster count also surged (Figure 6B).
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3. Discussion
Overall, 58.4% (45/77) of the total CTCs analyzed in our study were CTC clusters;
80.0% (40/50) of CTCs isolated from patients with metastasis were CTC clusters, while
81.5% (22/27) of CTCs from patients with locally advanced disease were single CTCs.
Remarkably, 85% (34/40) of CTC clusters in patients with metastasis were from the RP-M
group. The presence of CTC clusters is known to be a prognostic factor for PDAC for
both PFS and OS. While our findings support the findings of previous studies suggesting
a higher metastatic potential of CTC clusters [10,20], we have further characterized the
molecular phenotype of individual CTCs and CTC clusters.
Based on the analysis of the heterogeneous population of PDAC CTC clusters in terms
of epithelial vs. mesenchymal phenotype, mesenchymal markers were the highest in CTC
clusters (63.60%) and in the RP-M group (78.98%), which confirms the findings of previous
studies reporting the mesenchymal characteristics of CTC clusters. It is worth mentioning
that the fact that mesenchymal markers are highest in clusters may not necessarily mean
that the tumor cells inside the clusters are mesenchymal, but the clusters are heterotypic
and contain accessory cells from blood lineage that do express mesenchymal markers. In
addition to the well-known mesenchymal markers vimentin and SNAI1 [40], SPARC was
also included because of the highly positive correlation with mesenchymal markers such
as vimentin, ZEB1, N-cadherin, and Twist and the highly negative correlation with the
epithelial marker E-cadherin [26,41]. Although it is not a major fraction, 22.2% (10/45) of
CTC clusters were of epithelial type, which were assumed to be disseminated from primary
cancer via non-EMT-mediated invasion, thus retaining their epithelial characteristics during
circulation [11,42]. In our study, only one among the total 10 epithelial CTC clusters
originated from a patient in the RP-M group.
egarding the presence of other cells in T clusters traveling together in the blood-
strea , e ser e latelet ar ers i 80 (36 45) f t e t tal cl sters, a 43.8
f si l s (14 32) were platelet-associated. Intriguingly, 91% (31/34) of TC clus-
ters d tected in the RP-M group had plat let marker expre sion. Moreover, l t
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showed various combinations of RNA expressions related to immune cells. Among the
45 CTC clusters, 60% had a positive expression for macrophage markers, 57.78% showed
neutrophil marker expression, and 44.44% had fibroblast marker expression. Remarkably,
macrophage- (92.6%), neutrophil- (88.5%), and fibroblast-associated (75.0%) CTC clusters
also showed positive platelet marker expression. It is implied that platelets may have
influenced the recruitment of immune and stromal cells to form CTC clusters.
There is mounting evidence suggesting the important role of platelets in tumor cell
circulation in blood and cancer metastasis [30–39]. Platelets form aggregates with tumor
cells by binding to tumor-derived tissue factor and thrombin, which can protect CTC
clusters from shear stress or immune attacks in the bloodstream [30–35]. They also promote
metastasis by helping the adhesion of CTCs to endothelial cells of the vessel wall and
form early metastatic niches [30–35]. Platelets are known to have direct interaction with
immune cells and modulate the immune response during inflammation [33]. The interplay
of platelets with tumor cells has been utilized both in cancer diagnostics and advanced
therapies [36–39]. Moreover, emerging evidence supports the heterogeneity in the complex
composition of CTC clusters [43]. For example, studies having an in-depth understanding
of the roles of tumor-associated macrophages [44,45], neutrophils [23], and carcinoma-
associated fibroblasts [46] in promoting tumor metastasis have been reported.
Although the importance of platelet-covered CTC clusters is recognized, few studies
have reported the specific molecular characterization and clinical significance of platelets
in tumor progression. Jiang et al. observed platelet-covered CTCs from patients with lung
and breast cancers using a platelet-specific CD41 antibody-coated microfluidic chip [32].
Aceto et al. detected platelet markers in both single CTCs and CTC clusters isolated from
breast cancer patients [11]. Beck et al. revealed that the expression of platelet-associated
genes in CTCs and cell-free RNA was associated with patients’ survival [30]. In our study,
we could isolate single CTCs and CTC clusters using the FAST disc from a prospective
cohort of PDAC patients and demonstrate the prognostic value of platelet-covered CTCs
using a comprehensive single-cell mRNA expression analysis.
Although the importance of CTC clusters in cancer metastasis and disease outcome
has been highly recognized [10,11,13], studies on the molecular characteristics of PDAC
CTCs and CTC clusters at a single-cell level are limited [25–27], partly because of the
difficulties associated with the rare, fragile, and heterogeneous nature of CTCs. In our
study, single-cell mRNA expression analysis of CTCs and CTC clusters was performed
using label-free isolation of CTCs from the whole blood of patients using the FAST disc [28].
Since CTCs may undergo phenotype change through EMT and hide in stealth mode for
immune escape, a surface-marker-independent CTC isolation approach was chosen. The
gentle spinning of the disc at FAST mode (600 rpm, <20 G-force) [28] allowed ultrafast
(<20 s for 3 mL of whole-blood filtration) CTC isolation with a reduced pressure drop
(~1 kPa); CTCs and CTC clusters were not stuck inside of the pore but sat on top of the
membrane (Figure S2). Thus, it was easy to pick single cells and intact clusters and use live
cells directly, without fixing, for more efficient single-cell gene expression analysis [29].
There are some important limitations to our study. First, the number of samples was
small. A further study in a larger cohort is needed to explore clinical implications. Second,
although we used an epitope-independent approach to isolate CTCs, small-sized cells
were not captured on the filter membrane, and therefore, the analysis could be biased
to the group of cells > 8 µm. Third, despite the fast collection of live CTCs from whole
blood, several CTCs (15 samples among a total of 92 CTCs, 16%) had low-quality RNA
and were thus excluded from the analysis. While the FAST disc has a lower failure rate
than other live CTC capture methods (~41%) [25,26,47], it needs to be improved in future
work. It is worth noting that all low-quality RNA samples belonged to patients in the
non-RP-M group with only one or two isolated CTCs. Although all the blood samples in
our study were processed within 6 h after blood withdrawal, reducing the sample transfer
time before starting the enrichment process may help. Fourth, the current gene expression
panel was designed to differentiate between epithelial and mesenchymal CTCs and to
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identify the presence of other blood cells in alliance with CTCs. Future studies may include
more markers associated with drug resistance and disease progression and preferably
RNA sequencing of CTC clusters dissociated into individual cells to have a broader and
single-cell-level understanding of CTC clusters. Additionally, it would be valuable to have
a molecular analysis of CTCs in early-stage cancer samples to determine whether a specific
category of CTC subpopulation has prognostic value.
4. Materials and Methods
4.1. Study Design and Clinical Sample Collection
This is a prospective cohort study that recruited 16 participants in a single tertiary re-
ferral center in South Korea. Inclusion criteria were (1) age ≥ 50 years; (2) locally advanced
or metastatic pancreatic cancer diagnosed using ultrasound, computed tomography (CT),
and magnetic resonance images; and (3) histologically confirmed as PDAC. Blood draws
were collected at baseline and during image workup after treatment every 2–3 months. In-
formed consent was obtained from all patients. The ethics committee of the internal review
board of Pusan National University Hospital approved the study (H-H-1801-020-062). The
clinical research information service approved the study (KCT0003511).
4.2. Label-Free Isolation of CTCs Using a Fluid-Assisted Separation Technology (FAST) Disc
The blood samples were collected in K2-EDTA tubes after discarding the first 1~2 mL
of blood to avoid contamination with skin epithelial cells [48]. We used a commercialized
version of the lab-on-a-disc equipped with FAST [28] on the CD-PRIME™ system (Cli-
nomics, Ulsan, Korea) to isolate intact CTCs from whole blood. The CD-CTC™ Duo is a
centrifugal microfluidic device for label-free, size-based CTC isolation that can be operated
using a standalone spinning system, CD-OPR-1000™. Rapid (>3 mL of whole blood/min)
and clog-free isolation of CTCs from the whole blood without any pretreatment steps was
enabled using tangential flow filtration on a FAST disc [28,29].
4.3. Imaging of CTCs by Immunofluorescence Staining
In addition to the mRNA-expression-based CTC analysis, we also performed conven-
tional immunofluorescence staining and image-based CTC enumeration. The immunos-
taining process was also performed on the disc. Subsequent to fixation of the captured cells,
the cells were permeabilized with 0.1% Triton X-100 in PBS for 5 min and then washed with
PBS. Then, the blocking step with 20 µg/mL of IgG was followed by staining with several
antibodies. To stain the white blood cells, anti-CD45-conjugated PE/Alexa Fluor 610 (H130,
Life Technologies, Carlsbad, CA, USA) was injected, incubated for 20 min, and then washed
with 0.01% Tween 20 in PBS. Next, the CTCs were stained with a mixture of anti-cytokeratin-
conjugated FITC (CAM5.2, BD, San Jose, CA, USA), anti-pan-cytokeratin-conjugated Alexa
488 (AE1/AE3, eBioscience, San Diego, CA, USA), and anti-EpCAM-conjugated FITC (9C4,
BioLegend, San Diego, CA, USA). A mixture of these antibodies was introduced to the
filter, incubated for 20 min, and then washed with 0.01% Tween 20 in PBS. Finally, the
nuclei in the cells were stained with 4,6-diamidino-2-phenylindole (DAPI) [28]. Cells that
were CK+/EpCAM+, CD45−, DAPI+, and morphologically intact were identified as CTCs,
while CD45+ and DAPI+ cells were identified as WBCs. To confirm the presence of platelets
in CTC clusters, anti-CD62P-conjugated APC (AK4, BioLegend, San Diego, CA, USA) was
added for staining p-selectin of platelets. Stained cells were automatically imaged through
a BioView workstation (BioView, Inc., Rehovot, Israel) for 10× images. A Nikon AR1
confocal microscope was used to obtain 60× fluorescence images.
4.4. Scanning Electron Microscope (SEM) Images of CTCs
To obtain SEM images, fixed cells were sequentially incubated in 5%, 10%, 20%,
40%, 60%, 80%, and 100% acetone for 20 min each followed by 2 h air-drying in between.
Dehydrated cells were Au-sputtered and imaged using a Hitachi S-4800 Cold FE-SEM
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(Hitachi High-Technologies, Tokyo, Japan). All images were obtained under identical
conditions at 5.00 kV accelerating voltage.
4.5. Cell Culture
Gene expression was validated using five types of pancreatic cancer cell lines, namely
BxPC-3, Capan-1, PANC-1, HPAC, and MIA PaCa-2, purchased from the American Type
Culture Collection (ATCC, Manassas, VA, USA). HPAC, PANC-1, and MIA PaCa-2 were
cultured in DMEM containing 10% FBS and 1× antibiotic-antimycotic solution. BxPC-3
and Capan-1 were cultured in RPMI medium with 10% FBS and 1× antibiotic-antimycotic
solution. All cells were cultured under 5% CO2 at 37 ◦C.
4.6. Single-Cell Isolation and Gene Expression Analysis
Individual CTCs showing CD45− and DAPI+ expression and CTC clusters captured
on the membrane were targeted for single-cell isolation using CellCelector™ (ALS, Jena,
Germany) and subject to mRNA profiling. A CTC cluster composed of two or more CTCs
(Figures 1B, S1 and S3) was treated as one sample without dissociation. Single-cell cDNA
was prepared using a Single Cell-to-Ct kit (Life Technologies, New York, NY, USA) and
a pre-amplified specific target for gene expression analysis (Life Technologies, NY, USA).
Quantitative reverse-transcription polymerase chain reaction was performed with the
BioMark HD real-time PCR system (Fluidigm, South San Francisco, CA, USA). The list of
genes used in our study is summarized in Supplementary Table S1.
4.7. Comprehensive Characterization of Single CTCs and CTC Clusters
Utilizing mRNA expression data from single CTCs and CTC clusters, we characterized
CTCs into three categories: epithelial, stem-cell-like, and mesenchymal CTCs. Similar to
our previous study [29], KRT7, KRT19, and CDH1 were used as characteristic markers
for epithelial CTCs; CD44, NANOG, and PROM1 were used as markers for stem-cell-like
CTCs; and vimentin, SPARC, and SNAI1 were used as markers for mesenchymal CTCs.
mRNA expression of single CTCs and CTC clusters was normalized to that of GAPDH
and calculated as the difference between the target gene Ct and GAPDH Ct values (2−∆Ct).
Scores according to each type were defined as the sum of 2−∆Ct values across the markers of
each type. Finally, the total of scores from the three types was converted into a percentage.
Additionally, platelet markers such as ITGA2b, SELP, and PDGFb were evaluated for the
characterization of single CTCs and CTC clusters isolated from patients’ blood samples.
CTC clusters were further analyzed for macrophage, neutrophil, and fibroblast markers.
We used CD68, CD14, and ADGRE1 as macrophage markers; CD45, CSF3R, and ITGAM
as neutrophil markers; and S100A4 and THY1 as fibroblast markers.
4.8. Assessment of Progression-Free Survival and Overall Survival
PFS and OS were evaluated for patients with CTC clusters. If an outcome was not
reached, the time variables were censored at the last follow-up. Kaplan–Meier plots and the
log-rank test were used to illustrate and compare survival between the subgroups. Survival
analysis of variables measured at treatment-naïve baseline was performed. Univariate and
multivariate hazard ratios for selected potential predictors of PFS and OS were determined
using the Cox proportional hazards regression.
4.9. Statistical Analysis
Undetected genes were assigned a Ct value of 999, which were imputed using the
highest Ct value observed for a given gene plus a value of 1 to provide balanced weights
to missing data. All imputed Ct values in our statistical analyses were converted to
a Z-score to provide the same weights [26]. We conducted unsupervised hierarchical
clustering and t-distributed stochastic neighbor embedding (t-SNE) to explore associations
among sample groups. Unsupervised hierarchical clustering and its heat map visualization
were performed using the heatmap.2 function of the gplots package and t-SNE analysis
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was conducted using the Rtsne package for R (version 3.4.0, R Foundation for Statistical
Computing, Vienna, Austria, https://www.R-project.org/, accessed on 21 April 2017).
We used the corrplot package to visualize the correlation matrix, and p-values were
calculated using the cor.mtest function in R. The matrix shows pairwise Spearman rank
correlations between the expression levels of indicated mRNAs in cells. The correlation
matrix plots of correlations between the different expression levels of mRNAs measured
were constructed with the corrplot function supplied with the corrplot package in R; the
cor function was used to compute correlations. The correlation matrix was computed
separately for patient-derived CTCs from each patient with Spearman rank correlations.
Associated p-values were computed using the cor.mtest function in R. The Bonferroni
correction of p-values was performed to adjust for multiple testing in the rank correlation
matrix.
5. Conclusions
In conclusion, our study showed that CTC clusters, which showed mesenchymal
characteristics and platelet marker expression, were highly associated with poor prognosis,
including early death owing to rapid progression in metastasis. Furthermore, we confirmed
the relationship between the increase in CTC clusters and rapid disease progression during
follow-ups. Although further studies are needed to ascertain the clinical utility, these
initial results suggest the potential role of CTC clusters in the progression of cancer and
personalized medicine enabled using liquid biopsy.
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